Pharma & Biotech
  • Michalopoulou and Associates (Lawgroup) advised a Greek pharmaceutical company on the cancellation of the EOF Pharmaceutical Pricing Statement, achieving the determination of a correct producer price.
  • Michalopoulou and Associates (Lawgroup) advised a foreign consortium on the provision of medical services using stem cell products.
  • Michalopoulou and Associates (Lawgroup) advised a Greek pharmaceutical company on the annulment of a public tender for the illegal inclusion of one of the company's pharmaceutical products in the tender.
  • Michalopoulou and Associates (Lawgroup) advised a multinational pharmaceutical company on the possibility of supplying ATMPs on an ‘out-of-specification’ basis in Greece.
  • Michalopoulou and Associates (Lawgroup) advised a multinational healthcare company on pricing and reimbursement of next-generation sequencing tests used in cancerology in Greece.
  • Michalopoulou and Associates (Lawgroup) advised a leading pharma company on the establishment and corporate governance of a Biotechnology Park in Greece.
  • Michalopoulou and Associates (Lawgroup) composed the internal rules, procedures and policies on the regulatory issues of a multinational pharma company.
  • Michalopoulou and Associates (Lawgroup) advised a multinational pharma company before of the Greek Ministry of Health (HTA) regarding the marketing authorosation license of a medicine in the Greek market.
TOP